Last reviewed · How we verify
Pramipexole (Mirapex)
Pramipexole is a dopamine agonist that stimulates D2 and D3 dopamine receptors in the brain to restore dopamine signaling.
Pramipexole is a dopamine agonist that stimulates D2 and D3 dopamine receptors in the brain to restore dopamine signaling. Used for Parkinson's disease, Restless legs syndrome.
At a glance
| Generic name | Pramipexole (Mirapex) |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Dopamine agonist |
| Target | D2 dopamine receptor, D3 dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Pramipexole selectively binds to dopamine receptors, particularly D2 and D3 subtypes, in brain regions affected by neurodegeneration. By mimicking dopamine's action, it compensates for the loss of dopamine-producing neurons, thereby alleviating motor symptoms in Parkinson's disease and reducing the sensory and motor symptoms of restless legs syndrome.
Approved indications
- Parkinson's disease
- Restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Somnolence
- Insomnia
- Hallucinations
- Orthostatic hypotension
- Impulse control disorders
Key clinical trials
- Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy (PHASE4)
- Single-dose,First-in-human of KLA478 (PHASE1)
- Pramipexole and the Risk of Serious Adverse Events
- Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV (PHASE2)
- Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (PHASE3)
- Phase III Long-Term Extension Study With Dexpramipexole (PHASE3)
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pramipexole (Mirapex) CI brief — competitive landscape report
- Pramipexole (Mirapex) updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI